About US
Contact us
-
Regeneron wins FDA approval for rare immune disease med VeopozAlong with resolving site inspection issues that cost Regenerona high-dose Eylea launch in June, the company has scored an FDA nod forVeopoz as the first treatment for the ultra-rare inherited immune2023/8/4
-
On blockbuster mission, Merck says Welireg hit endpoint in renal cell carcinoma trialTwo years after Welireg's original approval in the rare von Hippel-Lindau (VHL) disease, Merck is looking to expand its drug'sreach and turn it into a blockbuster. The drug, which Merck p2023/8/4
-
Moderna's updated COVID shot stands strong against new variants in first look at trial data, company saysVexed by plummeting demand for their shots, COVID-19 vaccine producers are anxiously awaiting the fall inoculation season to get a glimpse of the post-pandemic market landscape, which includes a shif2023/8/1
-
Novartis floats share distribution scheme as it plots Sandoz spinoff for Oct. 4Novartis’ Sandoz spinoff is right around the corner, and, to celebrate the occasion, the Swiss pharma is plotting a special stock distribution scheme. Roughly a year after disclosing plan2023/8/1
-
Bayer pledges $500K in drugs and cash relief to Maui following devastating wildfiresIn the aftermath of devastating wildfires on Maui, Bayer is standing up as one of the first pharmaceutical companies to offer relief. The German conglomerate isprovidinga cash donation of2023/7/28
-
GSK stays a step ahead in RSV vaccine battle as Arexvy becomes available at US pharmaciesAs companies have flocked to compete in the new respiratory syncytial virus (RSV) vaccine market, GSK has had the best timing. In May, the U.K. company was first tosecure2023/7/28
-
GSK yanks 2 batches of its asthma blockbuster Nucala in Taiwan over glass particle fearsIn the world of drug packaging, a vial is a vial, the product the product, and never the twain shall meet. When those standards start to slip, recalls are sure to follow. No2023/7/24
-
UK's Upperton wraps up £15M manufacturing expansion projectUpperton Pharma Solutions, a U.K.-based CDMO,put the finishing toucheson a 15 million pound sterling ($19.6 million) expansionof its manufacturing facility near its headquarters in Nottingham. Wit2023/7/24
-
Catalent's Indiana site, linked with Regeneron's high-dose Eylea rejection, dinged with 3 FDA observationsAfter Regeneron’s high-dose Eylea received a surprising FDA snub, the FDA disclosed cleaning and procedural issues at Catalent, the manufacturer linked with the rejection. Regeneronattributedthe r2023/7/20
-
MilliporeSigma earmarks $25M to expand dry powder cell operationsMilliporeSigma, Merck KGaA’s life science arm, plans to spend $25 millionas part of an expansion project at its dry powder cell culture media facility in the Kansas City suburb of Lenexa, Kansas.2023/7/20